Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2018 at "In Vivo"
DOI: 10.21873/invivo.11418
Abstract: Background: Alectinib is a new standard treatment for treatment-naïve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC); however, resistance ultimately develops in almost all patients, and data regarding the efficiency of ceritinib for such… read more here.
Keywords: alk positive; ceritinib; non small; positive non ... See more keywords